BIW-8962
- Generic Name
- BIW-8962
Two-Part, Open-Label, Multi-Center, Phase 1/2 Study of BIW-8962 as Monotherapy in Subjects With Lung Cancer
Phase 1
Terminated
- Conditions
- Phase 1 Portion : Non Small Cell Lung Cancer(NSCLC), Small Cell Lung Cancer(SCLC), MesotheliomaPhase 2 Portion : Small Cell Lung Cancer(SCLC)
- Interventions
- First Posted Date
- 2013-07-12
- Last Posted Date
- 2024-04-25
- Lead Sponsor
- Kyowa Kirin Korea Co., Ltd.
- Target Recruit Count
- 37
- Registration Number
- NCT01898156
- Locations
- 🇰🇷
For additional information regarding investigative sites for this trial, contact Kyowa Hakko Kirin Korea, Seoul, Korea, Republic of
Phase 1/2 Study of Anti GM-2 Monoclonal Antibody To Treat Multiple Myeloma
- First Posted Date
- 2008-10-20
- Last Posted Date
- 2024-04-25
- Lead Sponsor
- Kyowa Kirin Co., Ltd.
- Target Recruit Count
- 23
- Registration Number
- NCT00775502
- Locations
- 🇺🇸
Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, United States
🇺🇸Taussig Cancer Center- Cleveland Clinic, Cleveland, Ohio, United States
🇺🇸H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath